Abstract

This studies paper explores the function of metformin in improving lipid profile parameters and lowering cardiovascular risk factors in patients with diabetes mellitus (DM) and ischemic coronary heart disease (IHD). The look at consists of three companies of Iraqi patients: diabetic, diabetic with IHD, and IHD only patients. The parameters evaluated consist of lipid profile, atherogenic index, LDL/HDL ratio, HbA1c degrees, and oxidative pressure markers. The findings advocate that metformin treatment leads to a extensive decrease in LDL cholesterol, an increase in HDL cholesterol, and upgrades in different lipid profile parameters. Furthermore, metformin demonstrates a massive lower in HbA1c stages, indicating its capacity to lessen thrombotic chance. The paper also highlights the antioxidant impact of metformin, as evidenced by a decrease in oxidative stress markers. These effects guide the function of metformin as a secondary choice to lessen the risk of cardiovascular events in patients with DM and IHD.